From the Annual Report:
"Invion has completed most of the preclinical studies required before the start of clinical trials. There are a few bodies of work
that are currently in progress, such as dose range finding and formulation optimisation and bioavailability, that are expected
to be completed in the coming months."
Will be unlikely this year according to the above.
GLTA
Ann: Photosoft Territory Expanded to South Korea for Cancer, page-10
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IVX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $26.41M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 23 | 9849314 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 6053724 | 25 |
View Market Depth
| Last trade - 16.12pm 11/07/2024 (20 minute delay) ? |
| IVX (ASX) Chart |
Day chart unavailable